Evidence map›Paper›PMID 17340127›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2007

The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.

D T Beattie, M Cheruvu, N Mai, M O'Keefe, S Johnson-Rabidoux, C Peterson, E Kaufman, R Vickery

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. The Pharmacokinetics of Subcutaneous Methylnaltrexone Bromide in Rhesus Macaques (Journal of the American Association for Laboratory Animal Science : JAALAS · 2023
    Article
  3. Article
  4. Article
  5. Pharmacologic Profile of Naloxegol, a Peripherally ActingThe Journal of pharmacology and experimental therapeutics · 2017
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. New approaches to the treatment of opioid-induced constipation.European review for medical and pharmacological sciences · 2008
    Review
  13. Methylnaltrexone in the treatment of opioid-induced constipation.Clinical and experimental gastroenterology · 2008
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

D T BeattieDepartment of Pharmacology, Theravance Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA. dbeattie@theravance.com
M Cheruvu
N Mai
M O'Keefe
S Johnson-Rabidoux
C Peterson
E Kaufman
R Vickery
Theravance Biopharma (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study characterized the pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, its metabolite, ADL 08-0011, and methylnaltrexone. The activities of the compounds were investigated with respect to human or guinea pig opioid receptor binding and function in recombinant cell lines and mechanical responsiveness of the guinea pig ileum. Alvimopan and ADL 08-0011 had higher binding affinity than methylnaltrexone at human mu opioid receptors (pK (i) values of 9.6, 9.6, and 8.0, respectively). The compounds had different selectivities for the mu receptor over human delta and guinea pig kappa opioid receptors. ADL 08-0011 had the highest mu receptor selectivity. With respect to their mu opioid receptor functional activity ([(35)S]GTPgammaS incorporation), methylnaltrexone had a positive intrinsic activity, consistent with partial agonism, unlike alvimopan and ADL 08-0011, which had negative intrinsic activities. Alvimopan, ADL 08-0011, and methylnaltrexone antagonized inhibitory responses mediated by the mu opioid agonist, endomorphin-1 (pA (2) values of 9.6, 9.4, and 7.6, respectively) and by U69593, a kappa opioid agonist (pA (2) values of 8.4, 7.2, and 6.7, respectively). In morphine-naive guinea pig ileum, methylnaltrexone reduced, while alvimopan and ADL 08-0011 increased, the amplitude of electrically evoked contractions and spontaneous mechanical activity. In tissue from morphine-dependent animals, alvimopan and ADL 08-0011 increased spontaneous activity to a greater degree than methylnaltrexone. The data suggested that alvimopan-induced contractions resulted predominantly from an interaction with kappa opioid receptors. It is concluded that alvimopan, ADL 08-0011, and methylnaltrexone differ in their in vitro pharmacological properties, particularly with respect to opioid receptor subtype selectivity and intrinsic activity. The clinical significance of the data from this study remains to be determined.

Indexed as

Narcotic AntagonistsAnalgesics, OpioidAnimalsBenzeneacetamidesCHO CellsCricetinaeCricetulusDose-Response Relationship, DrugEnkephalin, Ala(2)-MePhe(4)-Gly(5)-Guanosine 5'-O-(3-Thiotriphosphate)Guinea PigsHumansIleumIn Vitro TechniquesMaleMorphineADL 08-0011alvimopanAnalgesics, OpioidBenzeneacetamidesendomorphin 1Enkephalin, Ala(2)-MePhe(4)-Gly(5)-Guanosine 5'-O-(3-Thiotriphosphate)methylnaltrexoneMorphineNaltrexoneNarcotic AntagonistsOligopeptidesPiperidinesPyrrolidinesQuaternary Ammonium CompoundsReceptors, OpioidReceptors, Opioid, deltaReceptors, Opioid, kappaReceptors, Opioid, muRecombinant ProteinsU 69593

Identifiers

PMID17340127
OpenAlexW1993121666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.